Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment
July 1st 2016Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).
Read More